Which cancers respond to immunotherapy and targeted drugs using real-world patient data
Project 3: Predictors of sensitivity to immunotherapy and targeted treatments based on real world evidence
Using a large clinical-genomic database to find which patients with specific tumor genes are most likely to benefit from immunotherapy or targeted medicines.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11181558 on NIH RePORTER |
What this research studies
You would not need to join a new treatment trial for this work — researchers will analyze existing cancer genetics and treatment records from the AACR Project GENIE database. They will link molecular features of tumors (for example BRAF changes or high tumor mutation burden) to what happened after patients got immune checkpoint inhibitors or targeted drugs. The team will pay special attention to uncommon driver mutations and to tumor-agnostic biomarkers that apply across cancer types. By pooling many real-world cases, they hope to learn what works when prospective trials are impractical.
Who could benefit from this research
Good fit: People with cancer who have had tumor genomic testing or who received immunotherapy or targeted treatments are the kinds of patients whose records are most useful to this project.
Not a fit: People without tumor genomic testing, those with non-cancer conditions, or patients not represented in the clinical-genomic records are unlikely to see direct benefit from this project.
Why it matters
Potential benefit: If successful, this could help doctors pick immunotherapy or targeted drugs more accurately for people based on their tumor genetics.
How similar studies have performed: Previous registry and real-world genomic studies have identified biomarker-treatment links for some mutations and for markers like TMB, but using pooled clinical-genomic data to clarify rare or pan-cancer scenarios is an expanding and still-developing approach.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Schultz, Nikolaus — Sloan-Kettering Inst Can Research
- Study coordinator: Schultz, Nikolaus
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.